Denali Therapeutics’ brain-crossing drug hits market

AVLAYAH brought in $3.6 million in its first quarter, as Denali advanced its Alzheimer’s pipeline and banked $195m from a voucher sale. California-based Denali Therapeutics has posted its first quarterly revenue as a commercial-stage company, reporting $3.6 million in net product revenue from AVLAYAH (tividenofusp alfa-eknm) in the second quarter of 2026, its first full […] The post Denali Therapeutics’ brain-crossing drug hits market appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.